权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Altered Lipid Metabolism as a Novel Target for Colon Cancer Treatment

改变脂质代谢作为结肠癌治疗的新目标

基本信息

批准号：
10227741
负责人：
Bernard Mark Evers
金额：
$ 42.53万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10227741
关键词：
Acute Address Apoptosis Attention Behavior Benign Biological Biological Models Biological Sciences Cancer Cell Growth Cancer Etiology Carnitine Cell Death Cell Proliferation Cell Survival Cells Cessation of life Clinical Trials Collaborations Colon Colon Carcinoma Colorectal Cancer DNA Sequence Alteration Development Dose Enzymes Epithelial Cells Etiology Excision Fatty Acids Fatty-acid synthase Future Glucose Glycolysis Goals Growth Hepatic Individual Laboratories Lead Lipids Lung Malignant - descriptor Malignant Neoplasms Measures Mediating Membrane Lipids Metabolic Metabolism Mitochondria Mucous Membrane Non-Small-Cell Lung Carcinoma Oncogenic Oral Ovarian Oxidative Stress Palmitates Pharmacodynamics Pharmacologic Substance Phospholipids Production RNA Interference Research Resected Respiration Signal Pathway Slice Techniques Technology Therapeutic Therapeutic Agents Tissues Triglycerides Tumor Angiogenesis United States Up-Regulation Warburg Effect antitumor effect base beta catenin cancer cell cell growth cell transformation chemotherapy colon cancer patients colon cancer treatment colorectal cancer metastasis colorectal cancer progression experimental study extracellular fatty acid biosynthesis fatty acid metabolism in vivo inhibitor/antagonist innovation lipid biosynthesis lipid metabolism membrane synthesis metabolomics multidisciplinary neoplastic neoplastic cell new therapeutic target novel novel therapeutic intervention overexpression patient derived xenograft model patient subsets personalized approach randomized placebo-controlled clinical trial response secondary endpoint small molecule inhibitor stable isotope treatment strategy triple-negative invasive breast carcinoma tumor tumor growth tumor metabolism tumorigenesis

项目摘要

Altered cellular metabolism has been widely recognized as an emerging hallmark of cancer. Although recent advances in cancer metabolism research have begun to elucidate how metabolic changes support cancer cell growth and survival, alterations in fatty acid (FA) metabolism in cancer cells have received less attention. Increasing evidence has suggested that increased FA biosynthesis is needed not only to accommodate high rates of proliferation by providing building blocks for membrane synthesis, but also to enhance the ability of cancer cells to defend against oxidative stress- or chemotherapy-induced cell death by changing membrane lipid composition. Studies from our laboratories and others have demonstrated that FA synthase (FASN), a key enzyme of de novo lipid biosynthesis, is significantly upregulated in colorectal cancer (CRC). Our in vivo studies demonstrate that RNAi-mediated inhibition of FASN markedly reduces lung and hepatic CRC metastases and inhibits tumor angiogenesis. Collectively, our studies indicate FASN may serve as a potential target for novel therapeutic agents. Recently, several orally-available, reversible, potent and selective FASN small molecule inhibitors have been developed by our collaborator 3-V Biosciences. These agents have excellent pharmaceutical profiles and achieve antitumor effects at tolerated doses in a broad range of tumors including non-small cell lung cancer, ovarian and triple negative breast cancers. The translational goal of our project is to define the metabolic adaptations that occur in colon cancer and to conduct a clinical trial to evaluate the effect of FASN inhibitor, TVB-2640, on modulating cellular metabolism and proliferation in colon cancer patients. The central hypothesis for our proposal is that upregulation of FASN expression and activity occurs in a subset of colon cancer patients; therefore, these individuals would benefit from a therapeutic approach that includes targeted inhibition of de novo lipogenesis. The following Specific Aims are proposed: 1) to determine the effect of altered FASN expression on metabolic reprograming in colon cancer; 2) to delineate the anti-proliferative effect of FASN inhibition using patient-derived xenograft (PDX) models of colon cancer; and 3) to perform a pilot clinical trial in collaboration with 3-V Biosciences to assess pharmacodynamic effects on metabolic endpoints following short-term treatment with a novel FASN inhibitor (TVB-2640) prior to colon resection. Our highly collaborative group has the requisite expertise, innovative model systems, state-of-the-art technology and novel inhibitors to make rapid progress that will significantly advance our understanding of the FASN-mediated metabolic alterations of colon cancers and potentially provide novel treatment strategies based on a more focused and personalized approach.

细胞代谢改变已被广泛认为是癌症的一个新兴标志。虽然